Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Study AOP 03-007 was designed as a pivotal study to test, if Anagrelide (Thromboreductin®)was not inferior to HU with respect to efficacy in patients with ET. This approach to demonstrate non-inferiority was based on the following decision points:

• ET is a rare disease and recruitment of large patient number (> 1600) to prove superiority was not considered possible.

. It was decided to recruit only treatment naïve high risk patients to avoid pre-treatment bias, which further limited the number of patients eligible for the study.

• Phase: Phase 3

Details

• Lead Sponsor: AOP Orphan Pharmaceuticals AG
• Treatments: Anagrelide; Hydroxyurea

Criteria

Inclusion Criteria:

• Presence of essential thrombocythaemia with high-risk profile.

Exclusion Criteria:

• previous treatment with cytoreductive drugs or Anagrelide

• pregnant women or women in childbearing age with inadequate contraception

• patients with contraindications for study drugs due to anaphylactoid reactions to either active or non-active ingredients

• known lactose intolerance

• cardiovascular diseases grade III-IV (Toxicity Criteria of the South West Oncology Group, 1992) - with a negative benefit/risk ratio

• severe renal disease (Creatinin Clearance < 30 ml/min)

• severe liver disease (AST or ALT > 5-times normal)

• coexisting, malignant, systemic diseases